Toll-like receptor 2 and 6 interdependency in the erosive stage of Staphylococcus aureus induced septic arthritis mediated by IFN-γ and IL-6 - A possible involvement of IL-17 in the progression of the disease

Immunobiology

Volumn 220, Issue 7, 2015, Pages 910-923

  Ghosh, Chandrayee ^a   Bishayi, Biswadev ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

Lymphoid organs; Neutralization; Septic arthritis; Swiss albino mouse; Synovial mononuclear cells; Toll like receptor 6 (TLR 6)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; HYDROGEN PEROXIDE; IL10 PROTEIN, MOUSE; NITRIC OXIDE; TLR2 PROTEIN, MOUSE; TLR6 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM IDENTIFICATION; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; BLOOD; CYTOLOGY; IMMUNOLOGY; INFECTIOUS ARTHRITIS; INFLAMMATION; LYMPH NODE; MACROPHAGE; METABOLISM; MICROBIOLOGY; SPLEEN; SYNOVIUM;

ANIMALS; ARTHRITIS, INFECTIOUS; HYDROGEN PEROXIDE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; LYMPH NODES; MACROPHAGES; MALE; MICE; NITRIC OXIDE; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SYNOVIAL MEMBRANE; TH1 CELLS; TH17 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929504675     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.01.012     Document Type: Article

References (69)

1. Amat M., Benjamim C.F., Williams L.M., Prats N., Terricabras E., Beleta J., Kunkel S.L., Godessart N. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br. J. Pharmacol. 2006, 149:666-675.
2. Arnold C.E., Gordon P., Barker R.N., Wilson H.M. The activation status of human macrophages presenting antigendetermines the efficiency of Th17 responses. Immunobiology 2015, 220:10-19.
3. Arnold S.R., Elias D., Buckingham S.C., Thomas E.D., Novais E., Arkader A., Howard C. Changing patterns of acute hematogenous osteomyelitis and septic arthritis: emergence of community-associated methicillin-resistant Staphylococcus aureus. J. Pediatr. Orthop. 2006, 26:703-708.
4. Asanuma M., Kurokawa K., Ichikawa R., Ryu K., Chae J., Dohmae N., Lee B.L., Nakayama H. Structural evidence of a-aminoacylated lipoproteins of Staphylococcus aureus. FEBS J. 2011, 278:716-728.
5. Aslam R., Speck E.R., Kim M., Crow A.R., Bang K.W., Nestel F.P., Ni H., Lazarus A.H., Freedman J., Semple J.W. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-a production in vivo. Blood 2006, 107:637-641.
6. Bishayi B., Bandyopadhyay D., Majhi A., Adhikary R. Effect of exogenous MCP-1 on TLR-2 neutralized murine macrophages and possible mechanisms of CCR-2/TLR-2 and MCP-1 signalling during Staphylococcus aureus infection. Immunobiology 2014, (in press). 10.1016/j.imbio.2014.10.013.
7. Bondeson J., Wainwright S.D., Lauder S., Amos N., Hughes C.E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res. Ther. 2006, 8:R187. 10.1186/ar2099.
8. Brentano F., Schorr O., Gay R.E., Gay S., Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005, 52:2656-2665.
9. Bukharie H.A. Increasing threat of community-acquired methicillin-resistant Staphylococcus aureus. Am. J. Med. Sci. 2010, 340:378-381.
10. Buwitt-Beckmann U., Heine H., Wiesmüller K.H., Jung G., Brock R., Akira S., Ulmer A.J. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur. J. Immunol. 2005, 35:282-289.
11. Buwitt-Beckmann U., Heine H., Wiesmüller K.H., Jung G., Brock R., Akira S., Ulmer A.J. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J. Biol. Chem. 2006, 281:9049-9057.
12. Caiello I., Minnone G., Holzinger D., Vogl T., Prencipe G., Manzo A., De Benedetti F., Strippoli R. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS ONE 2014, 9:e107886. 10.1371/journal.pone.0107886.
13. Chen N., Huang M., Hsieh S. Enhanced secretion of IFN-g by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine. J. Immunol. 2001, 166:270-276.
14. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 2000, 1:510-514.
15. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 2008, 180:5771-5777.
16. Deiters U., Gumenscheimer M., Galanos C., Mühlradt P.F. Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect. Immun. 2003, 71:4456-4462.
17. Devlin J., Gough A., Huisson A., Perkins P., Holder R., Reece R., Arthur V., Emery P. The acute phase and function in early rheumatoid arthritis, C-reactive protein levels correlate with functional outcome. J. Rheumatol. 1997, 24:9-13.
18. Dillon S., Agrawal A., Dyke T.V., Landreth G., McCauley L., Koh A., Maliszewski C., Akira S., Pulendran B. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 2004, 172:4733-4743.
19. Finnegan A., Mikecz K., Tao P., Glant T.T. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J. Immunol. 1999, 163:5383-5390.
20. Fong D.J., Hogaboam C.M., Matsuno Y., Akira S., Uematsu S., Joshi A.D. Toll-like receptor 6 drives interleukin-17A expression during experimental hypersensitivity pneumonitis. Immunology 2010, 130:125-136.
21. Fournier B., Philpott D.J. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 2005, 18:521-540.
22. Grabiec A., Meng G., Fichte S., Bessler W., Wagner H., Kirschning C.J. Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides. J. Biol. Chem. 2004, 279:48004-48012.
23. Guo Y., Li J., Hagström E., Ny T. Protective effects of plasmin (ogen) in a mouse model of Staphylococcus aureus-induced arthritis. Arthritis Rheum. 2008, 58:764-772.
24. Hajjar A.M., O'Mahony D.S., Ozinsky A., Underhill D.M., Aderem A., Klebanoff S.J., Wilson C.B. Cutting edge: functional interactions between Toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J. Immunol. 2001, 166:15-19.
25. Hultgren O., Eugster H., Sedgwick J.D., Körner H., Tarkowski A. TNF/lymphotoxin-a double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J. Immunol. 1998, 161:5937-5942.
26. Hultqvist M., Olofsson P., Gelderman K.A., Holmberg J., Holmdahl R. A new arthritis therapy with oxidative burst inducers. PLoS Med. 2006, 3:e348. 10.1371/journal.pmed.0030348.
27. Iwanami K., Matsumoto I., Tanaka-Watanabe Y., Inoue A., Mihara M., Ohsugi Y., Mamura M., Goto D., Ito S., Tsutsumi A., Kishimoto T., Sumida T. Crucial role of the interleukin 6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008, 58:754-763.
28. Jung Y.O., Cho M., Lee S., Oh H., Park J., Park M., Park M., Ju J., Kim S., Park S., Kim H., Min J. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-α in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice. Immunol. Lett. 2009, 123:138-143.
29. Kang J.Y., Nan X., Jin M.S., Youn S.J., Ryu Y.H., Mah S., Han S.H., Lee H., Paik S.G., Lee J.O. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009, 31:873-884.
30. Kopp E., Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 2003, 15:396-401.
31. Kwan T.S., Padrines M., Théoleyre S., Heymann D., Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004, 15:49-60.
32. Lancioni C.L., Li Q., Thomas J.J., Ding X.D., Thiel B., Drage M.G., Pecora N.D., Ziady A.G., Shank S., Harding C.V., Boom W.H., Rojas R.E. Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4+ T cell activation via Toll-like receptors 1 and 2. Infect. Immun. 2011, 79:663-673.
33. Leigh P.C.J., van Furth R., van Zwet T.L. In vitro determination of phagocytosis and intracellular killing by polymorphonuclear and mononuclear phagocytes. Handbook of experimental Immunology 1986, Blackwell Scientific, Oxford, 46.1-46.26. D.M. Weir (Ed.).
34. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J.J., Joosten L.A.B., van den Berg W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004, 50:650-659.
35. Lukey P.T., Perry H.C., Yang S., Parry S., Dickson M.C., Norris V.H., Russell P.G., Watissée M., Rioja I., Ray K.P., Crowe S., Binks M. Single doses of p38 MAP kinase inhibitors or prednisolone affect CRP and IL-6 in patients with active rheumatoid arthritis (RA). Open J. Immunol. 2012, 2:85-97.
36. Mal P., Dutta S., Bandyopadhyay D., Dutta K., Basu A., Bishayi B. Gentamicin in combination with ascorbic acid regulates the severity of Staphylococcus aureus infection-induced septic arthritis in mice. Scand. J. Immunol. 2012, 76:528-540.
37. Mal P., Ghosh D., Bandyopadhyay D., Dutta K., Bishayi B. Ampicillin alone and in combination with riboflavin modulates Staphylococcus aureus infection induced septic arthritis in mice. Indian J. Exp. Biol. 2012, 50:677-689.
38. Malfait A.M., Butler D.M., Presky D.H., Maini R.N., Brennan F.M., Feldmann M. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 1998, 111:377-383.
39. McInnes I.B., Leung B., Wei X., Gemmell C.C., Liew F.Y. Septic arthritis following Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J. Immunol. 1998, 160:308-315.
40. McLoughlin R.M., Jones S.A., Topley N. Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest. 2003, 112:598-607.
41. Nakae S., Saijo S., Horai R., Sudo K., Mori S., Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5986-5990.
42. Nakao Y., Funami K., Kikkawa S., Taniguchi M., Nishiguchi M., Fukumori Y., Seya T., Matsumoto M. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. J. Immunol. 2005, 174:1566-1573.
43. Nandi A., Dey S., Biswas J., Jaiswal P., Naaz S., Yasmin T., Bishayi B. Differential induction of inflammatory cytokines and reactive oxygen species in murine peritoneal macrophages and resident fresh bone marrow cells by acute Staphylococcus aureus infection: Contribution of Toll-like receptor 2 (TLR2). Inflammation 2014, 10.1007/s10753-014-0026-8.
44. Nandi D., Mishra M.K., Basu A., Bishayi B. Protective effects of interleukin-6 in lipopolysaccharide (LPS)-induced experimental endotoxemia is linked to alteration in hepatic anti-oxidant enzymes and endogenous cytokines. Immunobiology 2010, 215:443-451.
45. O'Shea K., McCarthy T., Moore D., Dowling F., Fogarty E. Clinical and radiological outcome following neonatal septic arthritis. J. Bone Joint Surg. Br. 2003, 85. (B no. SUPP II 139).
46. Okusawa T., Fujita M., Nakamura J., Into T., Yasuda M., Yoshimura A., Hara Y., Akira H., Golenbock D.T., Morita M., Kuroki Y., Ogawa T., Shibata K. Relationship between structures and biological activities of Mycoplasmal diacylated lipopeptides and their recognition by Toll-like receptors 2 and 6. Infect. Immun. 2004, 72:1657-1665.
47. Osiri M., Ruxrungtham K., Nookhai S., Ohmoto Y., Deesomchok U. IL-1, IL-6 and TNF-a in synovial fluid of patients with non-Gonococcal septic arthritis. Asian Pac. J. Allergy Immunol. 1998, 16:155-160.
48. Pacquelet S., Presle N., Boileau C., Dumond H., Netter P., Martel-Pelletier J., Pelletier J.P., Terlain B., Jouzeau J.Y. Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J. Rheumatol. 2002, 29:2602-2610.
49. Papathanasiou I., Malizos K.N., Poultsides L., Karachalios T., Oikonomou P., Tsezou A. The catabolic role of toll-like receptor 2 (TLR-2) mediated by the NF-κB pathway in septic arthritis. J. Orthop. Res. 2011, 29:247-251.
50. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111:1805-1812.
51. Pierer M., Wagner U., Rossol M., Ibrahim S. Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1J mice. PLoS ONE 2011, 6:e23539. 10.1371/journal.pone.0023539.
52. Roelofs M.F., Joosten L.A.B., Abdollahi-Roodsaz S., van Lieshout A.W.T., Sprong T., van den Hoogen F.H., van den Berg W.B., Radstake T.R.D.J. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005, 52:2313-2322.
53. Ruschen S., Stellberg W., Warnatz H. Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls. Clin. Exp. Immunol. 1992, 89:32-37.
54. Seibl R., Birchler T., Loeliger S., Hossle J.P., Gay R.E., Saurenmann T., Michel B.A., Seger R.A., Gay S., Lauener R.P. Expression and regulation of Toll-like receptor 2 in, rheumatoid arthritis synovium. Am. J. Pathol. 2003, 162:1221-1227.
55. Simons D.M., Oh S., Kropf E., Aitken M., Garcia V., Basehoar A., Caton A.J. Autoreactive Th1 cells activate monocytes to support regional Th17 responses in inflammatory arthritis. J. Immunol. 2013, 190:3134-3141.
56. Smith J.W., Piercy E.A. Infectious arthritis. Clin. Infect. Dis. 1995, 20:225-230.
57. Sobek V., Birkner N., Falk I., Würch A., Kirschning C.J., Wagner H., Wallich R., Lamers M.C., Simon M.M. Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease. Arthritis Res. Ther. 2004, 6:R433-R446. 10.1186/ar1212.
58. St Clair E.W. Interleukin 10 treatment for rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58:99-102.
59. Strippoli R., Carvello F., Scianaro R., De Pasquale L., Vivarelli M., Petrini S., Bracci-Laudiero L., De Benedetti F. Amplification of the response to Toll-like receptor ligands by prolonged exposure to Interleukin-6 in mice implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012, 64:1680-1688.
60. Sugawara I., Yamada H., Li C., Mizuno S., Takeuchi O., Akira S. Mycobacterial infection in TLR2 and TLR6 knockout mice. Microbiol. Immunol. 2003, 47:327-336.
61. Takeuchi O., Hoshino K., Akira S. Cutting Edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000, 165:5392-5396.
62. Takeuchi O., Kaufmann A., Grote K., Kawai T., Hoshino K., Morr M., Mühlradt P.F., Akira S. Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 2000, 164:554-557.
63. Takeuchi O., Kawai T., Mühlradt P.F., Morr M., Radolf J.D., Zychlinsky A., Takeda K., Akira S. Discrimination of bacterial lipoporoteins by Toll-like receptor-6. Int. Immunol. 2001, 13:933-940.
64. Tarkowski A., Bokarewa M., Collins L.V., Gjertsson I., Hultgren O.H., Jin T., Jonsson I.M., Josefsson E., Sakiniene E., Verdrengh M. Current status of pathogenetic mechanisms in staphylococcal arthritis. FEMS Microbiol. Lett. 2002, 217:125-132.
65. Tawaratsumida K., Furuyashiki M., Katsumoto M., Fujimoto Y., Fukase K., Suda Y., Hashimoto M. Characterization of N-terminal structure of TLR2-activating lipoprotein in Staphylococcus aureus. J. Biol. Chem. 2009, 284:9147-9152.
66. Tissi L., Puliti M., Barluzzi R., Orefici G., von Hunolstein C., Bistoni F. Role of tumor necrosis factor alpha, interleukin-1b, and interleukin-6 in a mouse model of group b Streptococcal arthritis. Infect. Immun. 1999, 67:4545-4550.
67. Ultaigh S.N.A., Saber T.V., McCormick J., Connolly M., Dellacasagrande J., Keogh B., McCormack W., Reilly M., O'Neill L.A., McGuirk P., Fearon U., Veale D.J. Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Res. Ther. 2011, 13:R33.
68. Watanabe I., Ichiki M., Shiratsuchi A., Nakanishi Y. TLR2-mediated survival of Staphylococcus aureus in macrophages: a novel bacterial strategy against host innate immunity. J. Immunol. 2007, 178:4917-4925.
69. Whitehead A., Crawford D.L. Variation within and among species in gene expression: raw material for evolution. Mol. Ecol. 2006, 15:1197-1211.